Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, and Genetix Biotherapeutics Inc., a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, have expanded their manufacturing partnership to increase commercial-scale production of LYFGENIA, Genetix’s FDA-approved, one-time gene therapy for individuals 12 years and older with sickle cell disease.

The collaboration significantly increases manufacturing capacity, enabling Genetix to meet growing commercial demand while maintaining the quality, consistency, and regulatory rigor required for commercial CGT manufacturing.

To facilitate the expansion, Minaris Advanced Therapies has implemented process and operational improvements that increase manufacturing efficiencies and reduce turnaround times, while significantly increasing output. Minaris has continued to invest in infrastructure, talent, and capacity to ensure it can support long-term commercial supply and respond to increasing demand without disruption.

The collaboration reinforces Minaris’ broader mission to support advanced therapy developers through the transition from development to sustained commercial supply. With strengthened capacity and a focus on continuous improvement, Minaris is positioned to support Genetix’s growth while maintaining the operational excellence required for regulated commercial manufacturing.

Minaris, Genetix Leadership Reacts

“Minaris is proud to partner with Genetix to continue to bring this transformative therapy to patients. This expansion reflects the reality of commercial cell and gene therapies, where demand can increase quickly,” said Dr. Eytan Abraham, Chief Commercial & Technology Officer at Minaris. “Our focus is on investing early, building efficiency into the process, and ensuring our partners have the capacity and cost structure to scale as patient needs grow.”

“The increasing growth in commercial demand for LYFGENIA requires us to meaningfully expand our manufacturing capacity. Minaris has been a reliable, highly effective and innovative partner bringing our curative therapies to patients in need.,” said Brian Riley, President & Chief Technical Officer at Genetix. “They understand the technical demands of manufacturing a genetic therapy and have consistently demonstrated the essential capabilities needed to support our growing commercial supply needs.”